Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

Elaine T. Lam, S. Gail Eckhardt, Wells Messersmith, Antonio Jimeno, Cindy L. O'Bryant, Ramesk K Ramanathan, Glen J. Weiss, Manpreet Chadha, Abbie Oey, Han Ting Ding, Patricia A. Culp, Stephan F. Keller, Vivian Y. Zhao, L. Claire Tsao, Anil Singhal, Kyle D. Holen, Daniel Von Hoff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This phase I study evaluates the safety, MTD, pharmacokinetics (PK), pharmacodynamics, and preliminary anticancer activity of enavatuzumab, a humanized IgG1 antibody to the TWEAK receptor, in patients with advanced solid malignancies. Patients received escalating doses of enavatuzumab given intravenously over 60 minutes every 2 weeks. Blood was obtained for PK and biomarker assessment. Three patients were enrolled per dose level in a standard 3 + 3 design with response assessment by RECIST version 1.0, every 8 weeks. Thirty patients were enrolled at 6 dose levels ranging from 0.1 to 1.5 mg/kg. Dose-limiting toxicities included grade 4 (G4) lipase, G3 bilirubin, and G4 amylase elevations. There was no apparent correlation of liver or pancreatic enzyme elevation with drug exposure or the presence of liver metastases. Enavatuzumab exhibited a two-compartment linear PK model. Estimated systemic clearance was 23 to 33 mL/h with an elimination half-life of 7 to 18 days. The predicted target efficacious peak and trough concentrations occurred at 1.0 mg/kg following the second dose. There were no objective responses; 4 patients had stable disease. The MTD of enavatuzumab is 1.0 mg/kg i.v. every 2 weeks. Higher doses were not tolerated due to hepatopancreatic lab abnormalities. Further evaluation of the mechanisms of the liver and pancreatic enzyme toxicities is needed before embarking on further single-agent or combination strategies.

Original languageEnglish (US)
Pages (from-to)215-221
Number of pages7
JournalMolecular Cancer Therapeutics
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Antibodies, Monoclonal, Humanized
Pharmacokinetics
Neoplasms
Liver
Enzymes
Amylases
Lipase
Bilirubin
Half-Life
Linear Models
Immunoglobulin G
Biomarkers
enavatuzumab
TWEAK receptor
Neoplasm Metastasis
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors. / Lam, Elaine T.; Eckhardt, S. Gail; Messersmith, Wells; Jimeno, Antonio; O'Bryant, Cindy L.; Ramanathan, Ramesk K; Weiss, Glen J.; Chadha, Manpreet; Oey, Abbie; Ding, Han Ting; Culp, Patricia A.; Keller, Stephan F.; Zhao, Vivian Y.; Tsao, L. Claire; Singhal, Anil; Holen, Kyle D.; Von Hoff, Daniel.

In: Molecular Cancer Therapeutics, Vol. 17, No. 1, 01.01.2018, p. 215-221.

Research output: Contribution to journalArticle

Lam, ET, Eckhardt, SG, Messersmith, W, Jimeno, A, O'Bryant, CL, Ramanathan, RK, Weiss, GJ, Chadha, M, Oey, A, Ding, HT, Culp, PA, Keller, SF, Zhao, VY, Tsao, LC, Singhal, A, Holen, KD & Von Hoff, D 2018, 'Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors', Molecular Cancer Therapeutics, vol. 17, no. 1, pp. 215-221. https://doi.org/10.1158/1535-7163.MCT-17-0330
Lam, Elaine T. ; Eckhardt, S. Gail ; Messersmith, Wells ; Jimeno, Antonio ; O'Bryant, Cindy L. ; Ramanathan, Ramesk K ; Weiss, Glen J. ; Chadha, Manpreet ; Oey, Abbie ; Ding, Han Ting ; Culp, Patricia A. ; Keller, Stephan F. ; Zhao, Vivian Y. ; Tsao, L. Claire ; Singhal, Anil ; Holen, Kyle D. ; Von Hoff, Daniel. / Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 1. pp. 215-221.
@article{03c39a690e654a1fb11a05d6398d7a76,
title = "Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors",
abstract = "This phase I study evaluates the safety, MTD, pharmacokinetics (PK), pharmacodynamics, and preliminary anticancer activity of enavatuzumab, a humanized IgG1 antibody to the TWEAK receptor, in patients with advanced solid malignancies. Patients received escalating doses of enavatuzumab given intravenously over 60 minutes every 2 weeks. Blood was obtained for PK and biomarker assessment. Three patients were enrolled per dose level in a standard 3 + 3 design with response assessment by RECIST version 1.0, every 8 weeks. Thirty patients were enrolled at 6 dose levels ranging from 0.1 to 1.5 mg/kg. Dose-limiting toxicities included grade 4 (G4) lipase, G3 bilirubin, and G4 amylase elevations. There was no apparent correlation of liver or pancreatic enzyme elevation with drug exposure or the presence of liver metastases. Enavatuzumab exhibited a two-compartment linear PK model. Estimated systemic clearance was 23 to 33 mL/h with an elimination half-life of 7 to 18 days. The predicted target efficacious peak and trough concentrations occurred at 1.0 mg/kg following the second dose. There were no objective responses; 4 patients had stable disease. The MTD of enavatuzumab is 1.0 mg/kg i.v. every 2 weeks. Higher doses were not tolerated due to hepatopancreatic lab abnormalities. Further evaluation of the mechanisms of the liver and pancreatic enzyme toxicities is needed before embarking on further single-agent or combination strategies.",
author = "Lam, {Elaine T.} and Eckhardt, {S. Gail} and Wells Messersmith and Antonio Jimeno and O'Bryant, {Cindy L.} and Ramanathan, {Ramesk K} and Weiss, {Glen J.} and Manpreet Chadha and Abbie Oey and Ding, {Han Ting} and Culp, {Patricia A.} and Keller, {Stephan F.} and Zhao, {Vivian Y.} and Tsao, {L. Claire} and Anil Singhal and Holen, {Kyle D.} and {Von Hoff}, Daniel",
year = "2018",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0330",
language = "English (US)",
volume = "17",
pages = "215--221",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

AU - Lam, Elaine T.

AU - Eckhardt, S. Gail

AU - Messersmith, Wells

AU - Jimeno, Antonio

AU - O'Bryant, Cindy L.

AU - Ramanathan, Ramesk K

AU - Weiss, Glen J.

AU - Chadha, Manpreet

AU - Oey, Abbie

AU - Ding, Han Ting

AU - Culp, Patricia A.

AU - Keller, Stephan F.

AU - Zhao, Vivian Y.

AU - Tsao, L. Claire

AU - Singhal, Anil

AU - Holen, Kyle D.

AU - Von Hoff, Daniel

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This phase I study evaluates the safety, MTD, pharmacokinetics (PK), pharmacodynamics, and preliminary anticancer activity of enavatuzumab, a humanized IgG1 antibody to the TWEAK receptor, in patients with advanced solid malignancies. Patients received escalating doses of enavatuzumab given intravenously over 60 minutes every 2 weeks. Blood was obtained for PK and biomarker assessment. Three patients were enrolled per dose level in a standard 3 + 3 design with response assessment by RECIST version 1.0, every 8 weeks. Thirty patients were enrolled at 6 dose levels ranging from 0.1 to 1.5 mg/kg. Dose-limiting toxicities included grade 4 (G4) lipase, G3 bilirubin, and G4 amylase elevations. There was no apparent correlation of liver or pancreatic enzyme elevation with drug exposure or the presence of liver metastases. Enavatuzumab exhibited a two-compartment linear PK model. Estimated systemic clearance was 23 to 33 mL/h with an elimination half-life of 7 to 18 days. The predicted target efficacious peak and trough concentrations occurred at 1.0 mg/kg following the second dose. There were no objective responses; 4 patients had stable disease. The MTD of enavatuzumab is 1.0 mg/kg i.v. every 2 weeks. Higher doses were not tolerated due to hepatopancreatic lab abnormalities. Further evaluation of the mechanisms of the liver and pancreatic enzyme toxicities is needed before embarking on further single-agent or combination strategies.

AB - This phase I study evaluates the safety, MTD, pharmacokinetics (PK), pharmacodynamics, and preliminary anticancer activity of enavatuzumab, a humanized IgG1 antibody to the TWEAK receptor, in patients with advanced solid malignancies. Patients received escalating doses of enavatuzumab given intravenously over 60 minutes every 2 weeks. Blood was obtained for PK and biomarker assessment. Three patients were enrolled per dose level in a standard 3 + 3 design with response assessment by RECIST version 1.0, every 8 weeks. Thirty patients were enrolled at 6 dose levels ranging from 0.1 to 1.5 mg/kg. Dose-limiting toxicities included grade 4 (G4) lipase, G3 bilirubin, and G4 amylase elevations. There was no apparent correlation of liver or pancreatic enzyme elevation with drug exposure or the presence of liver metastases. Enavatuzumab exhibited a two-compartment linear PK model. Estimated systemic clearance was 23 to 33 mL/h with an elimination half-life of 7 to 18 days. The predicted target efficacious peak and trough concentrations occurred at 1.0 mg/kg following the second dose. There were no objective responses; 4 patients had stable disease. The MTD of enavatuzumab is 1.0 mg/kg i.v. every 2 weeks. Higher doses were not tolerated due to hepatopancreatic lab abnormalities. Further evaluation of the mechanisms of the liver and pancreatic enzyme toxicities is needed before embarking on further single-agent or combination strategies.

UR - http://www.scopus.com/inward/record.url?scp=85040067970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040067970&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0330

DO - 10.1158/1535-7163.MCT-17-0330

M3 - Article

VL - 17

SP - 215

EP - 221

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -